29 315

Cited 0 times in

Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.

Authors
Jeong, SH; Jung, JH; Han, JH; Kim, JH; Choi, YW; Lee, HW; Kang, SY; Hwang, YH; Ahn, MS; Choi, JH; Oh, YT; Chun, M; Kang, S; Park, KJ; Hwang, SC; Sheen, SS
Citation
Lung cancer (Amsterdam, Netherlands), 68(2):288-294, 2010
Journal Title
Lung cancer (Amsterdam, Netherlands)
ISSN
0169-50021872-8332
Abstract
BACKGROUND: Platinum-based concurrent chemoradiotherapy (CCRT) is a standard treatment for locally advanced unresectable non-small cell lung cancer (NSCLC). The determination of parameters that may predict the result of the treatment has strong clinical implications.

PATIENTS AND METHODS: Pretreatment tumor biopsy specimens from 39 patients with locally advanced NSCLC (stage IIIA: 5, stage IIIB: 34) were analyzed for p53, Bcl-2, Bax and ERCC1 expression by immunohistochemistry. All patients were treated with cisplatin-based CCRT. Twenty-four patients received induction chemotherapy followed by CCRT (60Gy/30 fractions, 6mg/m(2) of cisplatin daily). The most commonly administered induction chemotherapy regimen was VIP (etoposide, ifosfamide, cisplatin; 20 patients). Fifteen patients received the same CCRT without induction chemotherapy.

RESULTS: High expression of p53, Bcl-2, Bax and ERCC1 was observed in 15 (38%), 19 (49%), 17 (44%) and 12 (31%) patients, respectively. High expression of Bcl-2 was significantly associated with longer survival duration (20 months vs. 9 months, P=0.008) and better response to the treatment (74% vs. 30%, P=0.01). In multivariate analysis, Bcl-2 expression was the only significant independent prognostic factor of overall survival (P=0.007) among the pretreatment patients characteristics.

CONCLUSIONS: High expression of Bcl-2 may be a useful prognostic factor in locally advanced NSCLC patients treated with cisplatin-based CCRT.
MeSH terms
AdultAgedAntineoplastic Agents/*administration & dosage/adverse effectsCarcinoma, Non-Small-CellCisplatin/*administration & dosage/adverse effectsDNA-Binding Proteins/genetics/metabolismDisease ProgressionEndonucleases/genetics/metabolismFemaleHumansLung Neoplasms/*diagnosis/mortality/pathology/physiopathology/therapyMaleMiddle AgedPrognosisProto-Oncogene Proteins c-bcl-2/genetics/*metabolismRadiotherapy, AdjuvantTreatment OutcomeTumor Suppressor Protein p53/genetics/metabolismbcl-2-Associated X Protein/genetics/metabolism
DOI
10.1016/j.lungcan.2009.06.003
PMID
19560836
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
AJOU Authors
정, 성현한, 재호김, 장희이, 현우강, 석윤최, 진혁오, 영택전, 미선박, 광주황, 성철신, 승수
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse